Lab test could personalize brain tumor treatment

NCT ID NCT06620380

Recruiting now Knowledge-focused Sponsor: University of Zurich Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 30, 2026 · Updated 3 times

Summary

This study tests a lab technique called pharmacoscopy that quickly checks which drugs work best on a patient's own brain metastasis tissue. About 102 adults with brain metastases and few treatment options will have their tumor samples tested. The goal is to see if using this test to guide treatment improves survival compared to standard care.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Pharmacoscopy (a lab test to measure drug sensitivity on tumor samples)
What this could lead to: If successful, this approach could help doctors choose more effective treatments for brain metastases, especially when standard options are limited.
What could go wrong: This is a Phase 2 trial with only 102 participants, so results may not apply to everyone. The lab test may not always predict real-world drug response.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer metastatic malignant neoplasm in the brain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN METASTASES BRAIN METASTASES, ADULT

Contacts and locations

Locations

Cantonal Hospital St Gallen
NOT_YET_RECRUITING

Sankt Gallen, Switzerland
University Hospital Basel
RECRUITING

Basel, Switzerland
University Hospital Zurich
RECRUITING

Zurich, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.